C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 471/04 (2006.01) A61K 31/407 (2006.01) A61K 31/437 (2006.01)
Patent
CA 2748831
Beta-carboline derivatives of structural formula I are selective antagonists of the somatostatin subtype receptor 3 (SSTR3) and are useful for the treatment of Type 2 diabetes mellitus and of conditions that are often associated with this disease, including hyperglycemia, insulin resistance, obesity, lipid disorders, and hypertension. The compounds are also useful for the treatment of depression and anxiety.
La présente invention concerne des dérivés de la bêta-carboline de formule structurelle I qui sont des antagonistes sélectifs du sous-type de récepteur à la somatostatine 3 (SSTR3) et qui sont utiles pour le traitement du diabète sucré de type 2 et des pathologies qui sont souvent associées à cette maladie, parmi lesquelles l'hyperglycémie, la résistance insulinique, l'obésité, les troubles lipidiques, et l'hypertension. Les composés sont également utiles pour le traitement de la dépression et de l'anxiété. Formule (I).
Du Wu
Hagmann William K.
He Shuwen
Lai Zhong
Shah Shrenik K.
Merck Sharp & Dohme Corp.
Norton Rose Or S.e.n.c.r.l. S.r.l./llp
LandOfFree
Oxadiazole beta carboline derivatives as antidiabetic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Oxadiazole beta carboline derivatives as antidiabetic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oxadiazole beta carboline derivatives as antidiabetic compounds will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1714867